Background--Fibroblast growth factor-23 (FGF-23) is a hormone involved in phosphorous regulation and vitamin D metabolism that may be associated with cardiovascular risk, and it is a potential target for intervention. We tested whether elevated FGF-23 is associated with incident coronary heart disease, heart failure, and cardiovascular mortality, even at normal kidney function.
information is more limited, 18, 19 although it is suggestive of an association, particularly among individuals with impaired kidney function. 18, 19 Information is lacking for those with normal renal function, and prior studies have not had adequate power to examine these associations among African Americans. Using data from the prospective, community-based Atherosclerosis Risk In Communities (ARIC) Study, we tested the hypothesis that active, intact FGF-23 is positively associated with risk of incident CHD, HF, and cardiovascular mortality, independent of traditional cardiovascular risk factors and markers of kidney function.
Methods Study Population
The ARIC study is a population-based prospective cohort of 15 792 men and women (aged 45 to 64 years at baseline) who, between 1987 and 1989, were recruited from 4 US communities: Forsyth County, North Carolina; Jackson, Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland. 20 A total of 4 cohort reexaminations have taken place: 1990-1992 (visit 2), 1993-1995 (visit 3), 1996-1998 (visit 4), and 2011-2013 (visit 5). Local institutional review boards approved the ARIC protocol, and all participants gave informed consent. Serum FGF-23 was measured in samples collected at ARIC visit 2 (1990-1992) ; we are therefore using visit 2, which was attended by 14 348 participants, as "baseline" for the present analysis. Excluded from the analysis are participants who had prevalent CHD or HF at visit 2 (n=1368), self-identified as neither African American nor white and African Americans from the Minnesota and Maryland centers (n=85), had missing FGF-23 data (n=751), and had missing data on any covariate (n=506). Our final analytic sample included 11 638 participants.
FGF-23 and Other Variables
At visit 2, ARIC participants underwent interviews, fasting venipuncture, and measurement of blood pressure and anthropometrics. Trained interviewers ascertained basic demographic data, medical history, smoking status, and medication use. Participants were asked to bring to the visit all medications, vitamins, and supplements taken in the 2 weeks before the examination; all medication names were transcribed and coded. Physical activity (Baecke 21 questionnaire) was not assessed at visit 2, so values from visit 1 were carried forward. Height and weight were measured, and body mass index (BMI) calculated as weight/height 2 (kg/m 2 ).
Sitting blood pressure was measured in triplicate with a random-zero sphygmomanometer; the mean of the latter 2 measurements were used in this analysis. Diabetes was defined by fasting blood glucose >126 mg/dL, nonfasting glucose >200 mg/dL, a self-report of physician diagnosis, or current medication use for diabetes. Left ventricular hypertrophy was determined by the Cornell definition, based on 12-lead electrocardiograms. 22 Fasting (12-hour) blood samples were drawn, and plasma and serum were frozen at À70°C until analyzed. Intact FGF-23 was measured, in singlicate, in serum using a 2-site ELISA (FGF-23 ELISA Kit, Kainos Laboratories, Inc) at the Advanced Research and Diagnostic Laboratory, University of Minnesota, Minneapolis, Minnesota, in 2012-2013. The coefficient of variation (CV) for FGF-23 based on ARIC blind duplicate samples was 16.6%, while the CV from internal laboratory QC samples was 8.8% at 41.4 pg/mL. Serum phosphorus was measured in 2012-2013 on a Roche Modular P Chemistry Analyzer using a colorimetric method (CV=3%), and serum B-type natriuretic peptide (NT-proBNP) and serum highsensitivity troponin T (hs-TnT) were measured using sandwich immunoassay methods on a Roche Elecsys 2010 Analyzer (Roche Diagnostics Corporation). Lipids were measured at the time of ARIC visit 2 (1990-1992) . Total plasma cholesterol 23 and triglycerides 24 were determined via enzymatic methods.
High-density lipoprotein cholesterol (HDL-C) was measured after dextran-magnesium precipitation, 25 and the Friedewald equation 26 was used to calculate low-density lipoprotein cholesterol (LDL-C) in those with triglyceride levels <400 mg/ dL. Cystatin C was measured in 2012-2013 using the Gentian cystatin C reagent on the Roche Modular P Chemistry analyzer, and serum creatinine was measured in 1990-1992 using a modified kinetic Jaff e reaction. Estimated glomerular filtration rate (eGFR) was calculated using the 2012 CKD EPI equation, which incorporates both cystatin C and creatinine. 27 eGFR was categorized according to established clinical cutpoints: ≥90, 60 to 89, and 15 to 59 mL/min per 1.73 m 2 . No participants in our sample had an eGFR <15. Urine was not collected at ARIC visit 2 but was available at visit 4. Urinary creatinine was measured by the Jaffe method and albumin by a nephelometric method either on the Dade Behring BN100 (Dade Behring, Inc, Deerfield, IL) or Beckman Image Nephelometer. The albumin-creatinine ratio (ACR) was calculated. Prevalent CHD was defined by self-reported prior physician diagnosis of MI or coronary revascularization, prevalent MI by 12-lead ECG at visit 1, or an incident-adjudicated CHD event between ARIC visits 1 and 2. Preexisting HF was defined by any of the following: (1) an affirmative response to, "Were any of the medications you took during the last 2 weeks for heart failure?" (2) stage 3 or "manifest heart failure" according to Gothenburg criteria, 28, 29 
Statistical Analysis
Characteristics of participants at visit 2 are described using means and proportions, stratified by categories of FGF-23.
Pearson's correlation coefficients between key biomarkers are also provided. For the primary analysis, Cox proportional hazards regression was used to determine associations between FGF-23 and risk of incident CHD, HF, and cardiovascular mortality. Restricted cubic splines were used to explore the dose-response association between FGF-23 and outcomes and to aid in selecting the most appropriate exposure modeling. For all outcomes, there appeared to be a threshold whereby FGF-23 was unrelated to risk at levels <40 pg/mL but was associated with greater risk beyond that point. To convey this association, we used levels <40 pg/mL as the reference category (contains 45.3% of the analytic sample). Levels ≥40 pg/mL were divided into quartiles (each quartile contains 13.7% of the full study population Incident CHD (Table 2) . However, as illustrated in the restricted cubic spline models (Figure -Panel A), there was a threshold effect whereby there was no association between FGF-23 and risk at levels <40 pg/mL, but at >40 pg/mL there was a positive association. Hence, the reference group, which contains 45.3% of the full analytic sample, includes participants with FGF-23 concentrations <40 pg/mL. Levels >40 pg/mL were split into quartiles. After demographic adjustments, people in the highest category of FGF-23 (≥58.8 pg/mL) were at 1.65 (95% CI 1.40 to 1.94) times greater risk of incident CHD, relative to those at <40 pg/mL ( There was no evidence of interaction by age, sex, race, or eGFR on the association between FGF-23 and incident CHD. Given inherent interest, race-and eGFR-stratified results are presented in Tables 3 and 4 , respectively. Associations were qualitatively stronger in African Americans, relative to whites. It is important to note that in the analytic sample, only 309 ARIC participants had an eGFR <60 mL/min per 1.73 m 2 at visit 2.
Thus, power is more limited when restricted to this group. The relation between FGF-23 and incident HF was not modified by age, sex, or race, although qualitatively associations were somewhat stronger in blacks than in whites (Table 3 ). There was no statistically significant interaction of the HF and FGF-23 association by eGFR category; however, stratified results are presented in Table 4 .
Incident Cardiovascular Mortality
A total of 802 participants died of cardiovascular causes during follow-up. The median time to event was 11.2 (SD 4.1) years. A positive association was observed between FGF-23 when modeled per 1 SD and cardiovascular mortality. Similar to other outcomes, there was evidence of a threshold association (Figure -Panel C) . Relative to those with FGF-23 concentrations <40 pg/mL, those in the highest category (≥58.8 pg/mL) had a HR for cardiovascular mortality of 1.65 (1.36 and 2.01) after demographic adjustments (model 1) ( Table 2 ). In the fully adjusted model (model 4), the HR (top versus bottom category) for cardiovascular mortality was 1.28 (1.04 to 1.57). Results were similar when serum phosphorus Table 3) . eGFR category modified the association between FGF-23 and cardiovascular mortality in demographic-adjusted models (P-interaction=0.05) but not after accounting for behaviors and cardiovascular risk factors. eGFR-stratified results are presented in Table 4 .
Sensitivity Analyses
In sensitivity analyses, we explored the impact of adjusting for eGFR as a continuous variable and estimating GFR by using alternate equations. Results were similar regardless of how eGFR was modeled or calculated (data not shown). We also adjusted (separately) for ln(NT-proBNP) and ln(hs-TnT) and LVH presence by using the Cornell criteria. The results were attenuated only slightly (data not shown). Notably, the ARIC population was relatively young at visit 2, when the serum used for FGF-23 measurement was collected, and only 2% of the sample had LVH according to the Cornell criteria.
In order to further isolate our sample to people free of renal impairment, we restricted our analysis to participants who attended visit 4 (when urine was collected), were at visit 4 free of prevalent CHD or HF, had an albumin-to-creatinine ratio of >30 at visit 4, and an eGFR ≥60 at visit 2 (analytic sample=8397). After adjustment for cardiovascular risk factors, the HR's comparing those in the top FGF-23 category to those with FGF-23 <40 pg/mL were as follows: MI: 1.36 (1.06, 1.76); HF: 1.29 (1.04, 1.60), cardiovascular mortality: 1.57 (1.15, 2.14).
Discussion
In this large, biracial, population-based cohort, we observed a threshold effect in the association of FGF-23 and risk of incident CHD, HF, and cardiovascular mortality. A positive association was present between FGF-23 and risk of outcomes at FGF-23 levels above 40 pg/mL, whereas at levels <40 pg/mL there was no association. Relative to participants at <40 pg/mL, those in the highest category of FGF-23 (≥58.8 pg/mL) were at 44% greater risk of incident CHD, 46% greater risk of HF, and 51% greater risk of cardiovascular mortality, after adjustment for demographics, behaviors, and traditional cardiovascular risk factors. These associations were independent of serum phosphorus, and additional adjustment for markers of kidney function only modestly attenuated the associations. Furthermore, even 4, 5 and are known to increase dramatically in advanced CKD. 4, 46 It is difficult to disentangle the relations between FGF-23 and kidney function as estimated by using GFR. However, in the present analysis, associations between FGF-23 and incident CHD and HF were independent of eGFR and remained present when analyses were restricted to those with normal kidney function (eGFR ≥90 mL/min per 1.73 m 2 ), suggesting that FGF-23 may have actions independent of kidney disease quantified by reduced eGFR. We used both serum creatinine and cystatin to provide a better estimate of eGFR. 27 The Heart and Soul Study previously reported a positive association between FGF-23 and recurrent cardiovascular disease. 17 Identifying novel biomarkers for cardiovascular disease may enhance our etiologic understanding and improve our ability to identify high-risk individuals and possibly lead to new therapeutic targets. Importantly, given the relatively modest magnitudes of association between FGF-23 and the outcomes presented here, it is unlikely that the use of FGF-23 would improve risk prediction. However, because FGF-23 is physiologically active (unlike cystatin C and serum creatinine, which are markers for CKD, as opposed to causal risk factors), it may be a potential target for intervention. Three pharmacologic strategies have been proposed: oral phosphate binders, FGF-23 blocking agents, and FGF receptor antagonists. 3 Oral phosphate binders, the only of these options presently available, are commonly given to patients on dialysis and those with severe renal failure and have been shown to be effective in lowering FGF-23 levels. 48, 49 Clinical trials will need to demonstrate that lowering FGF-23 is efficacious in reducing cardiovascular disease (or possibly surrogates) and/or mortality before there would be justification for the widespread use of these agents. Strengths of this study are the prospective design, biracial population-based sample, detailed ascertainment of established cardiovascular risk factors, active outcome surveillance, large number of events, and corresponding power for subgroup analyses. Also, importantly, the assay used in the present study detects biologically active intact FGF-23, while many prior studies have used an assay that measures inactive C-terminal FGF-23 concentrations. Perhaps the major limitation of the present study is that FGF-23 was measured in singlicate at a single point in time and was associated with moderate analytic error (CV 16%). As a result, regression dilution bias may have attenuated relative hazard estimates. 50 This concept is supported by associations between FGF-23 and incident events being of greater magnitude when we restricted our analysis to the first 5 years of follow-up. HF events were identified through ICD codes from hospital discharge and death certificates; thus, cases of HF that were managed exclusively in outpatient settings would have been missed. However, ARIC has shown HF ICD codes to have high validity. 51 Last, as with all observational studies, it is possible that both residual and unmeasured confounding remained, despite our attempts at adjustment.
In conclusion, in this large, population-based cohort, high levels of FGF-23 were associated with greater risk of incident CHD, HF, and cardiovascular mortality. These associations were independent of traditional cardiovascular disease risk factors and were present both in the absence of reduced kidney function and among African Americans. These data are of interest from a pathophysiologic perspective and suggest the potential of FGF-23 as a target for therapeutic intervention to reduce risk of CHD, HF, and cardiovascular mortality.
